JAAD Comment Addresses 487-Gene Atopic Dermatitis Trial

By Daniel Okafor

A November 2026 comment in the Journal of the American Academy of Dermatology addresses a 487-gene expression profile test for systemic therapy selection in a prospective trial of patients with atopic dermatitis.

The comment appears in Volume 95, Issue 5. Its authors are Baharuddin Baharuddin, Lilies Handayani, and Maher Monir Akl.

The supplied citation gives no abstract or body text for the comment.

Without the authors’ reasoning or the trial’s numerical findings, no responsible report can assess how the test influenced treatment or whether patients benefited at all.

What does the trial paper claim?

The paper’s full title reads: “The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial.”

That title names the population, intervention, clinical purpose, and prospective design. It also asserts improved outcomes without quantifying them.

The citation identifies no enrollment size, patient demographics, comparator, systemic drug, follow-up duration, or primary endpoint. It also provides no assessment timing, safety outcome, or definition for “outcomes.”

A title can frame the research question, but only the full prospective report can show whether test-guided prescribing produced a measurable, credible treatment effect.

Takeaway: The title names the test, population, and design, but not the size of benefit.

What can readers quantify?

The short answer is none from this citation.

The record leaves these essential elements undisclosed:

• No participant count or demographic breakdown.
• No comparator, treatment list, follow-up period, or endpoint definition.
• No PASI or EASI change, itch result, quality-of-life result, or safety count.
• No effect estimate, confidence interval, P value, or missing-data account.
• No direct author quotation.

With every numerator, denominator, follow-up point, comparator, and uncertainty measure missing, readers cannot translate the paper’s outcome claim into a change for an individual patient.

A prospective design can support follow-up of patients, but the label alone does not disclose benefit, harm, or durability.

Takeaway: The citation supports a research claim, not a numerical clinical result.

Does this change treatment selection now?

Nothing in the citation establishes a new standard of care.

The record names no regulator, guideline panel, payer, or implementation body. It does not say whether the test is available for routine clinical use.

Nor does it identify which systemic therapies the profile might direct clinicians toward. That choice matters, but the source supplies no drug names or selection rules.

Until the full article supplies those details, the test remains a research subject in this record rather than a documented, practice-changing selection tool for patients with atopic dermatitis.

Takeaway: The citation alone does not justify changing systemic prescribing.

What would make the result assessable?

A defensible account needs at least the following details:

• The number of participants and their baseline disease severity.
• The systemic treatments compared and the protocol for treatment selection.
• The primary outcome, assessment time, and numerical difference between groups.
• The uncertainty around that difference, plus missing data and adverse events.
• The comment authors’ central criticism and the trial authors’ stated limitations.

Without those elements, “improve outcomes” remains a directional claim rather than a quantified clinical benefit. A news report cannot responsibly supply the missing denominator or infer an effect that the citation never states.

Takeaway: The next meaningful update will pair the full comment with the trial’s measured effect, precision, and limitations.